HER3-Targeted Therapies for EGFRm NSCLC: Key Evidence and Real-world Insights to Optimize Patient Care

Enhance your knowledge of HER3 overexpression in EGFR-mutated non-small-cell lung cancer and gain strategies for developing individualized treatment plans incorporating HER3-targeted therapies in patients with acquired resistance to EGFR tyrosine kinase inhibitors, through a series of text modules with accompanying downloadable slidesets and an expert-authored commentary.

Share

Program Content

Activities

HER3 EGFRm NSCLC Care
HER3-Targeted Therapies for EGFRm NSCLC: Emerging Therapies and Challenges in Treatment
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 09, 2024

Expires: October 08, 2025

Faculty

cover img faculity

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.